BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/13/2026 9:40:33 AM | Browse: 2 | Download: 0
 |
Received |
|
2026-01-21 06:40 |
|
Peer-Review Started |
|
2026-01-21 06:41 |
|
First Decision by Editorial Office Director |
|
2026-01-27 07:56 |
|
Return for Revision |
|
2026-01-27 11:39 |
|
Revised |
|
2026-02-09 08:13 |
|
Publication Fee Transferred |
|
2026-02-14 16:01 |
|
Second Decision by Editor |
|
2026-04-14 02:36 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-14 03:57 |
|
Articles in Press |
|
2026-04-14 03:57 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-17 07:15 |
|
Publish the Manuscript Online |
|
2026-07-13 09:40 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Prognostic factors and optimal timing for initiating adjuvant chemotherapy in stage IIIC gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jun-Wei Wu, Fan Li, Shi-Dian Wang, Yu-Kun Guo, Bing-Huang Li, Xin Zhou, Guo-Qiang Su and Chuan-Hui Lu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 81970462 |
| Key Medical and Health Project of Xiamen |
No. 3502Z20204001 |
|
| Corresponding Author |
Chuan-Hui Lu, /, The Graduate School of Fujian Medical University, No. 1 Xuefu North Road, Shangjie Town, Minhou County, Fuzhou 350122, Fujian Province, China. 46601533@qq.com |
| Key Words |
Gastric cancer; Chemotherapy; Disease-free survival; Prognosis; Time factors |
| Core Tip |
We identified age ≥ 60 years, carcinoembryonic antigen ≥ 5.0 μg/L, metastatic lymph node ratio ≥ 0.5 and time interval (TI) from surgery to initiation of adjuvant chemotherapy are independent risk factors for postoperative recurrence. Crucially, our findings demonstrate that initiating adjuvant chemotherapy within 6 weeks of surgery significantly improves disease-free survival in stage IIIC patients. Notably, the S-1 plus oxaliplatin regimen exhibits significant time-sensitivity, with an optimal window of within 6 weeks. Whereas the capecitabine plus oxaliplatin regimen does not. These insights provide a rationale for optimizing individualized therapeutic strategies for this high-risk subgroup. |
| Publish Date |
2026-07-13 09:40 |
| Citation |
Wu JW, Li F, Wang SD, Guo YK, Li BH, Zhou X, Su GQ, Lu CH. Prognostic factors and optimal timing for initiating adjuvant chemotherapy in stage IIIC gastric cancer. World J Gastrointest Oncol 2026; 18(7): 119040
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i7/119040.htm |
| DOI |
https://doi.org/10.4251/wjgo.v18.i7.119040 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
